BioAge Appoints Renowned Cardiologist and Biopharma Entrepreneur Michael H. Davidson, MD, to its Board of Directors
NewAmsterdam Pharma Company N.V. - Ordinary Shares (NAMS)
Company Research
Source: Business Wire
New board member brings deep expertise in cardiometabolic research, clinical development, and building successful biotech companies RICHMOND, Calif.--(BUSINESS WIRE)--BioAge Labs, Inc., ("BioAge"), a clinical-stage biotechnology company developing novel therapies for obesity and metabolic diseases by harnessing the biology of aging, today announced the appointment of Michael Davidson, MD to the company's board of directors."We are delighted to welcome Michael to BioAge's board of directors," said Kristen Fortney, PhD, CEO and co-founder of BioAge Labs. "His expertise as a physician and researcher in the field of cardiometabolism, deep experience in clinical development, and track record leading multiple successful companies will be invaluable to BioAge as we advance our lead compound azelaprag into a Phase 2 trial in combination with tirzepatide for the treatment of obesity."Davidson is CEO of NewAmsterdam Pharma (Nasdaq: NAMS), a late-stage biopharmaceutical company developing tra
Show less
Read more
Impact Snapshot
Event Time:
NAMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NAMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NAMS alerts
High impacting NewAmsterdam Pharma Company N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
NAMS
News
- NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024 [Yahoo! Finance]Yahoo! Finance
- NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024GlobeNewswire
- NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular DiseaseGlobeNewswire
- NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business OfficerGlobeNewswire
NAMS
Sec Filings
- 4/29/24 - Form PRE
- 4/19/24 - Form 424B3
- 4/18/24 - Form EFFECT
- NAMS's page on the SEC website